

EFdA-TP tetraammonium Biochemical | EFdA-TP biochemical

EFdA-TP tetraammonium

CATALOG #
AAA227057


PRODUCT SYNONYMS

EFdA-TP tetraammonium; EFdA-TP biochemical

PRODUCT SPECIFICATIONS


Purity/Purification	98%
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	EFdA-TP tetraammonium (0.05-10 uM; for 15 min) inhibits RT-catalyzed DNA synthesis as an ICT or DCT[1]. EFdA-TP tetraammonium can block RT as a translocation-defective RT inhibitor that dramatically slows DNA synthesis, acting as a de facto immediate chain terminator. EFdA-TP tetraammonium can function as a delayed chain terminator, allowing incorporation of an additional dNTP before blocking DNA synthesis[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure

Rac)-beta-Chamigrenic acid, CAS 1174388-31-8



Structure

Rac)-beta-Chamigrenic acid, CAS 1174388-31-8

ADDITIONAL INFORMATION

Related Product Information for EFdA-TP biochemical	EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits HIV-1 RT with multiple mechanisms[1].
References	1. Miran Jeong, et al. Kudsuphilactone B, a nortriterpenoid isolated from Schisandra chinensis fruit, induces caspase-dependent apoptosis in human ovarian cancer A2780 cells. Arch Pharm Res. 2017 Apr;40(4):500-508.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.